Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhoea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.
Contact us for detailed pricing information tailored to your specific needs and use cases.
Our advisory team comprises industry experts with extensive experience in drug development and delivery technologies.
Supported by leading investors committed to advancing innovative healthcare solutions.
Keylika is dedicated to developing breakthrough therapies at the critical intersection of drug discovery and drug delivery, ensuring superior clinical outcomes and improved patient compliance.
Match with like-minded professionals for 1:1 conversations
Go from Slack Chaos to Clarity in Minutes
Personalize 1000s of landing pages in under 30 mins
The first LLM for document parsing with accuracy and speed
AI Assistants for SaaS professionals
AI-powered phone call app with live translation
Delightful AI-powered interactive demos—now loginless
AI Motion Graphics Copilot
Pop confetti to get rid of stress & anxiety, 100% AI-free
Smooth payments for SaaS